This insight helps your PlexusDx provider choose between semaglutide, tirzepatide, or dual-compound therapy for maximum results tailored to your genetics
Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) Disease area(s): Oncology/hematology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $11.67 billion Why it sold so well: Anti-CD38 monoclonal antibody Darzalex and its subcutaneous formulation, Darzalex Faspro, had exceptional success in 2024, becoming J&Js top-selling pharmaceutical product with global net sales of $11.67 billion a 19.8% increase over 2023
As we look toward our health system's future, how we invest in our people is going to become more important than ever
There are higher chances of dosing error with this method
Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application